Summary of primary efficacy and safety outcomes across eligible trials. We present the outcomes reported in each individual trial as well as meta-analysis according to study design. Control refers to SOC alone without caplacizumab (refer to supplemental Table 2C “Details of treatments received”). Event rates refer to the number of patients with the event of interest. Below the pooled estimate of the risk difference, we present the same finding as the difference in absolute risk of the outcome among patients treated with caplacizumab plus SOC (compared with those treated with SOC alone) per 1000 patients treated with caplacizumab. Df, degrees of freedom; SD, standard deviation.